Comparative Pharmacology
Head-to-head clinical analysis: A HYDROCORT versus NASONEX 24HR ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A HYDROCORT versus NASONEX 24HR ALLERGY.
A-HYDROCORT vs NASONEX 24HR ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.
Glucocorticoid receptor agonist; inhibits inflammatory mediators including cytokines, chemokines, and adhesion molecules; reduces nasal inflammation.
Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.
2 sprays (50 mcg/spray) per nostril once daily; total dose 200 mcg/day.
None Documented
None Documented
Terminal half-life: 1.5-2 hours (cortisol); clinical effect persists 8-12 hours due to glucocorticoid receptor binding
The terminal elimination half-life of mometasone furoate is approximately 5.8 hours. This short half-life supports once-daily dosing for intranasal use, but systemic accumulation is minimal with topical administration.
Renal (primarily as metabolites, <1% unchanged); biliary/fecal (<5%)
Mometasone furoate is predominantly eliminated via biliary/fecal excretion. After intravenous administration, approximately 74% of the dose is recovered in feces and about 8% in urine. The drug undergoes extensive hepatic metabolism, and metabolites are excreted primarily in bile.
Category C
Category C
Corticosteroid
Corticosteroid, Intranasal